STAT9h
Alnylam drug wins FDA approval for progressive heart disease
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Novartis gets third FDA approval for oral Fabhalta
Novartis (NVS) announced that oral Fabhalta, iptacopan, has received U.S. Food and Drug Administration approval for the ...
Food Safety News20h
FDA unveils database about contamination levels in food
A new tool about chemical contaminants in human and animal foods is available from the FDA. The Chemical Contaminants Transparency Tool is the latest ...
China Medical System （00867） Released its 2024 Annual Results: Focusing on Innovation and Specialty Breakthroughs to Reshape Growth Momentum
However, for the Company, 2024 was both a “year of restructuring” amidst challenges and a “year of breakthroughs” with emerging potentials. Although the overall performance is experiencing short-term ...
Novartis23h
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
The New York Times14h
New York Times - Top Stories
Pentagon Set Up Briefing for Musk on Potential War With China The access would be a major expansion of Elon Musk’s government role and highlight his conflicts of interest. President Trump denied ...